Market Place
Sourcing Support
KORU Medical Announces Agreement Immunoglobulin Infusion
06 Feb 2025 //
BUSINESSWIRE
KORU Partners For Phase III Trial In Nephrology Drug Indication
30 Jan 2025 //
BUSINESSWIRE
KORU Medical Posts Record FY Revenue, Positive Cash Flow In Q4
13 Jan 2025 //
BUSINESSWIRE
KORU Medical Systems Reports Q3 Growth & Raises Full-Year Guidance
13 Nov 2024 //
BUSINESSWIRE
KORU Medical Presents Data on FreedomEdge® System at PODD
31 Oct 2024 //
BUSINESSWIRE
KORU Medical Systems Q3 2024 Financial Results on November 13
23 Oct 2024 //
BUSINESSWIRE
KORU Medical To Join Canaccord Genuity Growth Conference
25 Jul 2024 //
BUSINESSWIRE
KORU Medical Systems` FreedomEdge Infusion System Cleared In Japan
02 Jul 2024 //
BUSINESSWIRE
KORU Medical: Feasibility Study With Commercialized Oncology Biologic
04 Jun 2024 //
BUSINESSWIRE
KORU Signs Supply Deal For Novel Endocrinology Biologic Phase 3 Trial
14 May 2024 //
BUSINESSWIRE
KORU Medical Double-Digit Q1 2024 Revenue Growth
01 May 2024 //
BUSINESSWIRE
KORU Medical Systems Announces Successful Appeal in EU Notified Body Review
11 Apr 2024 //
BUSINESSWIRE
KORU Medical to Present Data Demonstrating 97% Adherence on Infusion System
18 Mar 2024 //
BUSINESSWIRE
KORU Medical Announces 2023 Fourth Quarter, Full Year Financial Results
13 Mar 2024 //
BUSINESSWIRE
KORU Medical Announces a Feasibility Study to Enter Ambulatory Infusion Settings
11 Mar 2024 //
BUSINESSWIRE
KORU Medical Signs a Agreement for Phase 3 Trial with Custom Device
06 Mar 2024 //
BUSINESSWIRE
KORU Medical to Report Fourth Quarter and Full Year 2023 Financial Results
21 Feb 2024 //
BUSINESSWIRE
KORU Medical to Participate in Piper Sandler’s 35th Annual Healthcare Conference
29 Nov 2023 //
BUSINESSWIRE
KORU Medical Systems, Inc. to Host Investor Day on December 5, 2023
28 Nov 2023 //
BUSINESSWIRE
KORU Medical Announces 2023 Third Quarter Financial Results
08 Nov 2023 //
BUSINESSWIRE
KORU Medical Systems, Inc. Appoints Ken Miller as Chief Commercial Officer
08 Nov 2023 //
BUSINESSWIRE
KORU Medical Announces Agreement for Immunoglobulin Infusion System
08 Nov 2023 //
BUSINESSWIRE
KORU Medical Receives FDA 510(k) Clearance for FREEDOM60® Infusion System
07 Nov 2023 //
BUSINESSWIRE
KORU Medical Systems to Participate in Upcoming Investor Conferences
02 Nov 2023 //
BUSINESSWIRE
KORU Systems to Report Third Quarter Financial Results on November 8, 2023
25 Oct 2023 //
BUSINESSWIRE
KORU to Participate in the Gilmartin Group Emerging Growth Company Showcase
15 Sep 2023 //
BUSINESSWIRE
KORU Medical Systems, Inc. Announces 2023 Second Quarter Financial Results
09 Aug 2023 //
BUSINESSWIRE
KORU Medical Systems to Participate in the Genuity 43rd Annual Growth Conference
08 Aug 2023 //
BUSINESSWIRE
KORU Medical Systems Announces Novel Therapies Collaboration
27 Jul 2023 //
BUSINESSWIRE
KORU Announces 510(K) Submission for Freedom60® Infusion System
10 Jul 2023 //
BUSINESSWIRE
KORU Medical Systems Announces 2022 Q4 and Full Year Financial Results
08 Mar 2023 //
BUSINESSWIRE
KORU Medical Systems to Report Fourth Quarter Financial Results on March 8, 2023
22 Feb 2023 //
BUSINESSWIRE
